Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 8/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335420 | 0.88 | NR4A2 (0.57) | HPGDSALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL26665315 | 0.84 | HPGDS (0.58) | HPGDSALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL2128899 | 0.82 | ALDH1A1 (0.72) | HPGDSALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL2127192 | 0.81 | ALDH1A1 (0.67) | HPGDSALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL2128357 | 0.81 | NPC1 (0.57) | HPGDSALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL1691332 | 0.80 | DYRK1A (0.60) | HPGDSALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL2127158 | 0.80 | APP (0.58) | HPGDSALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL26603229 | 0.78 | ALDH1A1 (0.56) | HPGDSALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL2426213 | 0.78 | APP (0.62) | HPGDSALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL4399834 | 0.77 | ALDH1A3 (0.56) | HPGDSALDH1A1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399476-B2 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | SANOFI (FR) | 2013-03-19 | — | — | US | claimed |
| EP-2129375-B1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-04-25 | — | — | EP | claimed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | claimed |
| EP-2129375-A1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-12-09 | — | — | EP | claimed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | claimed |
| EP-1964840-A1 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-09-03 | — | — | EP | claimed |
| US-8399476-B2 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| US-8399476-B2 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| US-8399476-B2 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| EP-2129375-B1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-04-25 | — | — | EP | disclosed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| EP-2129375-A1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | disclosed |
| EP-1964840-A1 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | NOS1, PTGIS, NOS2 | HPGDS 172/4885ALDH1A1 1286/4885KDM4E 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.